( IMBRUVICA ) Ibrushil Ibrutinib Capsules $39.90 – Rx Canada Pharmacy

$39.90

Placeholder

$39.90

Add to cart
Buy Now

( IMBRUVICA ) Ibrushil Ibrutinib Capsules 140mg – Rx Canada Pharmacy

Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton’s tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphomachronic lymphocytic leukemia, and Waldenström’s macroglobulinemia.

What is Ibrutinib 140mg Ibrushil Capsule?

International Brand       |          Medicine Trade Name  |          Manufacturer  |         Composition
 Imbruvica (Ibrutinib)                   Ibrushil 140mg Capsule              Shilpa Medicare         Ibrutinib (140mg)

Ibrutinib 140mg Ibrushil Capsule is a  prescription medication used in the treatment of mantle-cell lymphoma and blood cancer (chronic lymphocytic leukemia). It is also used in chronic lymphocytic leukemia and has received at least one prior therapy.`

Ibrutinib, sold under the brand name Imbruvica among others, is a small particle drug that ties for all time to a protein called Bruton’s tyrosine kinase (BTK), which is significant in B cells. It is utilized to treat B cell malignancies like mantle cell lymphoma, persistent lymphocytic leukemia, and Waldenström’s Macroglobulinemia.

Ibrutinib is accessible as a non-exclusive drug in the United States as of March 2021.

How is Ibrutinib 140mg Ibrushil Capsule used?

Ibrutinib is utilized to treat persistent lymphocytic leukemia (CLL), Waldenström’s Macroglobulinemia, and as second-line therapy for mantle cell lymphoma, peripheral zone lymphoma, and ongoing joining versus have the disease. BTK hindrance by ibrutinib weakens the BCR flagging pathway, which is a vital reliance on harmful B cells, yet it has been shown that BTK restraint additionally meddles with CD40 flagging, B cell grip, and relocation.

In the United States ibrutinib is shown for the therapy of grown-ups with mantle cell lymphoma (MCL) who have gotten no less than one earlier treatment, grown-ups with ongoing lymphocytic leukemia (CLL)/little lymphocytic lymphoma (SLL) with or without 17p erasure, grown-ups with Waldenström’s macroglobulinemia (WM), grown-ups with peripheral zone lymphoma (MZL) who require foundational treatment and have gotten somewhere around one earlier enemy of CD20-based treatment, grown-ups with persistent join versus have sickness (cGVHD) after the disappointment of at least one lines of fundamental treatment.

Side effects of Ibrutinib 140mg Ibrushil Capsule:

Ibrushil 140mg Capsule is taken in a dose as advised by the doctor. The duration of treatment varies based on your response to treatment. Your doctor may get regular blood tests to check the number of blood cells during treatment with this medicine. It is known to reduce the number of blood cells in your blood, thereby increasing the susceptibility to infections.  It may cause headaches, diarrhea, and nausea as its side effects.

Product Description

Ibrushil (Ibrutinib140mg) Capsule is used in the treatment of mantle-cell lymphoma and blood cancer (chronic lymphocytic leukemia). It is also used in chronic lymphocytic leukaemia who have received at least one prior therapy.

IBRUTINIB is indicated for the treatment of patients
• Mantle cell lymphoma (MCL) who have received at least one prior therapy
• Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
• Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)

Ibrushil 140mg Capsule is taken in a dose as advised by the doctor. The duration of treatment varies on the basis of your response to treatment. Your doctor may get regular blood tests to check number of blood cells during treatment with this medicine. It is known to reduce the number of blood cells in your blood thereby, increasing the susceptibility to infections.  It may cause headache, diarrhea, and nausea as its side effects.

USES OF IBRUSHIL CAPSULE

  • Mantle-cell lymphoma
  • Blood cancer (Chronic lymphocytic leukemia)

Ibrutinib 140mg Ibrushil Capsule

Trade Name:– Ibrushil

Manufacturer: Shilpa Medicare

Ibrutinib is accessible as a non-exclusive drug in the United States as of March 2021.

Ibrutinib 140mg Ibrushil Capsule comes from our international fulfillment center manufactured by Shilpa Medicare.
It is available in oral capsule form and one dosage strength of 140 mg.

Presentation: Capsule

Strength:  140mg

Medical uses

Ibrutinib is used to treat chronic lymphocytic leukemia (CLL), Waldenström’s macroglobulinemia, and as a second-line treatment for mantle cell lymphomamarginal zone lymphoma, and chronic graft vs host disease.[3][4] BTK inhibition by ibrutinib impairs the BCR signaling pathway, which is a key dependency of malignant B cells, but it has been shown that BTK inhibition also interferes with CD40 signaling, B cell adhesion and migration.

In the United States ibrutinib is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with or without 17p deletion, adults with Waldenström’s macroglobulinemia (WM), adults with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy, adults with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.[4][7][8][9][10]

It is a first line treatment in those with CLL who require treatment and are newly diagnosed.[11] It may also be used in CLL that relapses.[11]

Adverse effects

Very common (>10% frequency) adverse effects include pneumoniaupper respiratory tract infectionsinusitis, skin infection, low neutrophil countlow platelet counts, headache, bleeding, bruising, diarrhea, vomiting, inflammation of mouth and lips, nausea, constipation, rash, joint pain, muscle spasms, musculoskeletal pain, fever, and edema.[3]

Common (1–10% frequency) adverse effects include sepsisurinary tract infection, non-melanoma skin cancer (basal-cell carcinomasquamous cell carcinoma), low leukocyte countlow lymphocyte countinterstitial lung diseasetumor lysis syndrome,[12] high uric acid levelsdizziness, blurred vision, atrial fibrillationsubdural hematoma, nosebleeds, small bruises from broken blood vesselshigh blood pressurehives, and skin redness or blushing.[3]

Pharmacology

Ibrutinib oral bioavailability is 3.9% in a fasting state, 8.4% in a fed state, and 15.9% after consumption of grapefruit juice.[13]

Mechanism

Ibrutinib is a potent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue C481 in the BTK active site, leading to sustained inhibition of BTK enzymatic activity. BTK is an important signaling molecule of the B-cell antigen receptor (BCR) pathway, which is plays a role in the pathogenesis of several B-cell malignancies including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and chronic lymphocytic leukemia (CLL). Preclinical studies have shown that ibrutinib effectively inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.[5]

In early clinical studies, the activity of ibrutinib has been described to include a rapid reduction in lymphadenopathy accompanied by a transient lymphocytosis, suggesting that the drug might have direct effects on cell homing or migration to factors in tissue microenvironments.[14]

In preclinical studies on chronic lymphocytic leukemia (CLL) cells, ibrutinib has been reported to promote apoptosis, inhibit proliferation, and also prevent CLL cells from responding to survival stimuli provided by the microenvironment.[15] This also leads to a reduction of MCL1 levels (anti-apoptotic protein) in malignant B cells.[15] Treatment of activated CLL cells with ibrutinib resulted in inhibition of BTK tyrosine phosphorylation and also effectively abrogated downstream survival pathways activated by this kinase including ERK1/2PI3K, and NF-κB. Additionally, ibrutinib inhibited proliferation of CLL cells in vitro, effectively blocking survival signals provided externally to CLL cells from the microenvironment including soluble factors (BAFFIL-6IL-4, and TNF-α), fibronectin engagement and stromal cell contact.

Ibrutinib has also been reported to reduce chronic lymphocytic leukemia cell chemotaxis towards the chemokines CXCL12 and CXCL13, and inhibit cellular adhesion following stimulation at the B-cell receptor (BCR).[16][17] Additionally, ibrutinib down-modulates the expression of CD20 (target of rituximab/ofatumumab) by targeting the CXCR4/SDF1 axis.[15] Together, these data are consistent with a mechanistic model whereby ibrutinib blocks BCR signaling, which drives cells into apoptosis and/or disrupts cell migration and adherence to protective tumour microenvironments.

Strength140 mg
Packaging Size120 Capsule
BrandIbrushil
CompositionIbrutinib
ManufacturerShilpa Medicare Ltd
TreatmentBlood Cancer
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 years

SIDE EFFECTS OF IBRUSHIL CAPSULE
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them Common side effects of Ibrushil

  • Headache
  • Joint pain
  • Fever
  • Diarrhea
  • Vomiting
  • Stomatitis (Inflammation of the mouth)
  • Nausea
  • Constipation
  • Low blood platelets
  • Decreased white blood cell count (neutrophils)
  • Upper respiratory tract infection

HOW TO USE IBRUSHIL

Take this medicine in the dose and duration as advised by your doctor. Ibrushil 140mg Capsule may be taken with or without food, but it is better to take it at a fixed time.

HOW IBRUSHIL CAPSULE WORKS

Ibrushil 140mg Capsule is a Bruton’s tyrosine kinase inhibitor. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

SAFETY ADVICE

Alcohol: Consult your physician. It is not known whether it is safe to consume alcohol with Ibrushil 140mg Capsule. Please consult your doctor.

Pregnancy
Ibrushil 140mg Capsule is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.

Breastfeeding Caution:
Ibrushil 140mg Capsule should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.

Driving Unsafe:
Ibrushil 140mg Capsule may cause side effects which could affect your ability to drive.

Kidney Caution:
Ibrushil 140mg Capsule should be used with caution in patients with kidney disease. Dose adjustment of Ibrushil 140mg Capsule may be needed. Please consult your doctor.

Liver Caution:
Ibrushil 140mg Capsule should be used with caution in patients with liver disease. Dose adjustment of Ibrushil 140mg Capsule may be needed. Please consult your doctor.

Company Details:

Bull Pharmachem, is one of the largest Wholesale and retail distribution house for life saving generic medicines for Hepatitis C, Hepatitis B, HIV, Cancer and liver transplant.

Bull Pharmachem is a government authorized distributor and exporter of pharmaceutical products with all the necessary licenses to operate.

  • Products are sourced only from the factories in their country of origin which are approved by the FDA and are Good Manufacturing Practices (GMP) compliant to ensure highest standard of product quality.

Overdose:

If you think you have taken too much IMBRUVICA, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

IMPORTANT NOTE: References: https://en.wikipedia.org/wiki/Ibrutinib

The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.